Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: Evaluation of potential chemopreventive activity

Cancer

Volumn 118, Issue 23, 2012, Pages 5848-5856

  Curiel Lewandrowski, Clara ^a   Swetter, Susan M ^b   Einspahr, Janine G ^a   Hsu, Chiu Hsieh ^c   Nagle, Ray ^a   Sagerman, Paul ^a   Tangrea, Joseph ^d   Parnes, Howard ^d   Alberts, David S ^a   Chow, Hsiao Hui ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

anti inflammatory agents; atypical nevi; chemoprevention; melanoma; nevus; nonsteroidal; prevention and control

Indexed keywords

CASPASE 3; PLACEBO; SULINDAC; VASCULOTROPIN;

ABDOMINAL PAIN; ADULT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RISK; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPLASTIC NEVUS; FATIGUE; FEMALE; FLATULENCE; HEARTBURN; HUMAN; HUMAN TISSUE; HYPERTENSION; INCREASED APPETITE; MALE; MELANOMA; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; STOMACH PAIN; TINNITUS; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASPASE 3; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MELANOMA; MIDDLE AGED; NEVUS; SKIN NEOPLASMS; SULINDAC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84869493744     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27540     Document Type: Article

References (45)

1. American Cancer Society. Cancer Facts & Figures 2011. Atlanta, GA: American Cancer Society; 2011.
2. Halpern AC, Schuchter LM, Elder DE, et al. Effects of topical tretinoin on dysplastic nevi. J Clin Oncol. 1994; 12: 1028-1035. (Pubitemid 24145333)
3. Edwards L, Jaffe P,. The effect of topical tretinoin on dysplastic nevi. A preliminary trial. Arch Dermatol. 1990; 126: 494-499. (Pubitemid 20128963)
4. Edwards L, Meyskens F, Levine N,. Effect of oral isotretinoin on dysplastic nevi. J Am Acad Dermatol. 1989; 20: 257-260. (Pubitemid 19055634)
5. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer. 2005; 41: 28-44. (Pubitemid 40029657)
6. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005; 41: 45-60. (Pubitemid 40029658)
7. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer. 2005; 41: 2040-2059. (Pubitemid 41337946)
8. Shors AR, Kim S, White E, et al. Dysplastic naevi with moderate to severe histological dysplasia: a risk factor for melanoma. Br J Dermatol. 2006; 155: 988-993. (Pubitemid 44564509)
9. Chiu LC, Tong KF, Ooi VE,. Cytostatic and cytotoxic effects of cyclooxygenase inhibitors and their synergy with docosahexaenoic acid on the growth of human skin melanoma A-375 cells. Biomed Pharmacother. 2005; 59 (suppl 2): S293-S297.
10. Ottino P, Duncan JR,. Effect of vitamin E and indomethacin treatment on adenylate cyclase activity, PGE2 and cAMP levels in murine melanoma cells. Prostaglandins Leukot Essent Fatty Acids. 1997; 56: 143-149. (Pubitemid 27076245)
11. Roh JL, Sung MW, Kim KH,. Suppression of accelerated tumor growth in surgical wounds by celecoxib and indomethacin. Head Neck. 2005; 27: 326-332. (Pubitemid 40418605)
12. Duff M, Stapleton PP, Mestre JR, et al. Cyclooxygenase-2 inhibition improves macrophage function in melanoma and increases the antineoplastic activity of interferon gamma. Ann Surg Oncol. 2003; 10: 305-313. (Pubitemid 40486965)
13. Nakata K, Kashimoto S, Yoshida H, Oku T, Nakamura S,. Augmented antitumor effect of recombinant human interleukin-1 alpha by indomethacin. Cancer Res. 1988; 48: 584-588. (Pubitemid 18056526)
14. Harris RE, Beebe-Donk J, Namboodiri KK,. Inverse association of non-steroidal anti-inflammatory drugs and malignant melanoma among women. Oncol Rep. 2001; 8: 655-657.
15. Ramirez CC, Ma F, Federman DG, Kirsner RS,. Use of cyclooxygenase inhibitors and risk of melanoma in high-risk patients. Dermatol Surg. 2005; 31: 748-752. (Pubitemid 43110100)
16. Joosse A, Koomen ER, Casparie MK, Herings RM, Guchelaar HJ, Nijsten T,. Non-steroidal anti-inflammatory drugs and melanoma risk: large Dutch population-based case-control study. J Invest Dermatol. 2009; 129: 2620-2627.
17. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005; 294: 47-55. (Pubitemid 41002838)
18. Curiel-Lewandrowski C, Nijsten T, Gomez ML, Hollestein LM, Atkins MB, Stern RS,. Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol. 2011; 131: 1460-1468.
19. Athar M, An KP, Tang X, et al. Photoprotective effects of sulindac against ultraviolet B-induced phototoxicity in the skin of SKH-1 hairless mice. Toxicol Appl Pharmacol. 2004; 195: 370-378. (Pubitemid 38338658)
20. Izzotti A, Cartiglia C, Longobardi M, et al. Alterations of gene expression in skin and lung of mice exposed to light and cigarette smoke. FASEB J. 2004; 18: 1559-1561. (Pubitemid 39561632)
21. Kim DJ, Prabhu KS, Gonzalez FJ, Peters JM,. Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta). Carcinogenesis. 2006; 27: 1105-1112.
22. Annessi G, Bono R, Sampogna F, Faraggiana T, Abeni D,. Sensitivity, specificity, and diagnostic accuracy of three dermoscopic algorithmic methods in the diagnosis of doubtful melanocytic lesions: the importance of light brown structureless areas in differentiating atypical melanocytic nevi from thin melanomas. J Am Acad Dermatol. 2007; 56: 759-767. (Pubitemid 46561020)
23. Thompson PA, Hsu CH, Green S, et al. Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial. Cancer Prev Res (Phila). 2010; 3: 101-107.
24. Slade J, Marghoob AA, Salopek TG, et al. Atypical mole syndrome: risk factor for cutaneous malignant melanoma and implications for management. J Am Acad Dermatol. 1995; 32: 479-494.
25. Meyskens FL Jr, Edwards L, Levine NS,. Role of topical tretinoin in melanoma and dysplastic nevi. J Am Acad Dermatol. 1986; 15: 822-825. (Pubitemid 17170787)
26. Edwards L, Jaffe P,. The effect of topical tretinoin on dysplastic nevi. A preliminary trial. Arch Dermatol. 1990; 126: 494-499. (Pubitemid 20128963)
27. Halpern AC, Schuchter LM, Elder DE, et al. Effects of topical tretinoin on dysplastic nevi. J Clin Oncol. 1994; 12: 1028-1035. (Pubitemid 24145333)
28. Stam-Posthuma JJ, Vink J, le Cessie S, Bruijn JA, Bergman W, Pavel S,. Effect of topical tretinoin under occlusion on atypical naevi. Melanoma Res. 1998; 8: 539-548. (Pubitemid 29046505)
29. Dusza SW, Delgado R, Busam KJ, Marghoob AA, Halpern AC,. Treatment of dysplastic nevi with 5% imiquimod cream, a pilot study. J Drugs Dermatol. 2006; 5: 56-62.
30. Bayerl C, Schwarz B, Jung EG,. A three-year randomized trial in patients with dysplastic naevi treated with oral beta-carotene. Acta Derm Venereol. 2003; 83: 277-281. (Pubitemid 36920602)
31. Duggan DE,. Sulindac: therapeutic implications of the prodrug/pharmacophore equilibrium. Drug Metab Rev. 1981; 12: 325-337. (Pubitemid 12072724)
32. Duggan DE, Hooke KF, Risley EA, Shen TY, Arman CG,. Identification of the biologically active form of sulindac. J Pharmacol Exp Ther. 1977; 201: 8-13. (Pubitemid 8085991)
33. Vogt T, McClelland M, Jung B, et al. Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II. Melanoma Res. 2001; 11: 587-599. (Pubitemid 33152350)
34. Davies NM, Watson MS,. Clinical pharmacokinetics of sulindac. A dynamic old drug. Clin Pharmacokinet. 1997; 32: 437-459. (Pubitemid 27243647)
35. Monnier Y, Zaric J, Rüegg C,. Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: from the bench to the bedside and back. Curr Drug Targets Inflamm Allergy. 2005; 4: 31-38. (Pubitemid 40584850)
36. Tarnawski AS, Jones MK,. Inhibition of angiogenesis by NSAIDs: molecular mechanisms and clinical implications. J Mol Med. 2003; 81: 627-636. (Pubitemid 37357677)
37. Tu YT, Tao J, Liu YQ, et al. Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in human malignant melanoma and their relation to angiogenesis. Clin Exp Dermatol. 2006; 31: 413-418.
38. Simonetti O, Lucarini G, Brancorsini D, et al. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. Cancer. 2002; 95: 1963-1970. (Pubitemid 35222177)
39. Stefanou D, Batistatou A, Zioga A, Arkoumani E, Papachristou DJ, Agnantis NJ,. Immunohistochemical expression of vascular endothelial growth factor (VEGF) and C-KIT in cutaneous melanocytic lesions. Int J Surg Pathol. 2004; 12: 133-138. (Pubitemid 38542485)
40. Fröhlich E, Mack AF, Garbe C, Klessen C,. Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas. Br J Dermatol. 2005; 153: 1159-1165. (Pubitemid 41779571)
41. Pisacane AM, Risio M,. VEGF and VEGFR-2 immunohistochemistry in human melanocytic naevi and cutaneous melanomas. Melanoma Res. 2005; 15: 39-43. (Pubitemid 40354472)
42. Schietroma C, Cianfarani F, Lacal PM, et al. Vascular endothelial growth factor-C expression correlates with lymph node localization of human melanoma metastases. Cancer. 2003; 98: 789-797. (Pubitemid 36959276)
43. Achen MG, Williams RA, Minekus MP, et al. Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis. J Pathol. 2001; 193: 147-154. (Pubitemid 32118124)
44. Einspahr JG, Thomas TL, Saboda K, et al. Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression. Cancer. 2007; 110: 2519-2527. (Pubitemid 350174939)
45. Annessi G, Cattaruzza MS, Abeni D, et al. Correlation between clinical atypia and histologic dysplasia in acquired melanocytic nevi. J Am Acad Dermatol. 2001; 45: 77-85. (Pubitemid 32655699)